Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 1:41 AM
Ignite Modification Date:
2025-12-25 @ 1:41 AM
NCT ID:
NCT02331394
Eligibility Criteria:
Inclusion Criteria:
* Stages 4
* ECOG performance ≤ 3
* Life expectancy greater than ≥ 3 months
Exclusion Criteria:
* Receiving Tyrosine Kinase Inhibitors (TKI), (Tarceva, Iressa)
* Brain metastases
* Patients or families who do not speak English or French
* Abnormal liver function: Alanine aminotransaminase (ALT) \> 40 U/L, Aspartate aminotransaminase (AST) \> 55 U/L, Alkaline phosphatase (ALP) \> 145 U/L , Bilirubin \> 1.7 umol/L.
* Taking regular anti-convulsants, Coumadin or related anti-coagulant, lithium
* Taking regular immunosuppressive medications: azathioprine (Imuran), basiliximab (Simulect), cyclosporine (Neoral, Sandimmune), daclizumab (Zenapax), muromonab-CD3 (OKT3, Orthoclone OKT3), mycophenolate (CellCept), tacrolimus (FK506, Prograf), sirolimus (Rapamune)
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT02331394
Study Brief:
Protocol Section:
NCT02331394